To study whether pre-biopsy 3-Tesla prostate magnetic resonance imaging (MRI) with targeted biopsy allows accurate anatomical and oncological characterization of the index prostate tumour, and whether this translates into improved positive surgical margin (PSM) rates after radical prostatectomy.
Patients and Methods
We conducted a retrospective analysis of all men (n = 201) who underwent robot-assisted radical prostatectomy (RARP) between July 2012 and July 2014. Patients were divided into a study group (n = 63) who had undergone pre-biopsy 3-Tesla MRI, followed by visual targeted and systematic prostate biopsy, and a control group (n = 138) who had undergone systematic biopsy alone. The two groups were well matched regarding patient and cancer characteristics. The primary study objective was to assess the accuracy of pre-biopsy MRI for localizing the index tumour. Secondary study objectives were to assess the accuracy of MRI in assessing the maximum tumour diameter (MTD) of the index tumour focus and accuracy of the targeted biopsy in determining the Gleason score and primary Gleason grade of the index tumour focus and whether PSMs were improved after RARP. The reference standard was whole-gland pathology of the resected prostate gland. Continuous variables and proportions were compared using the t-test and Mann-Whitney test or contingency tables, respectively. Pearson's correlation coefficient and BlandAltman plots were used to compare measurement of MTD.
Results
The MRI accurately located the index tumour focus in 73% of patients. Accuracies, stratified according to use of the Prostate Imaging Reporting and Data System (PI-RADS) categories 5, 4 and 3, were 94, 75 and 60% respectively. Accuracies stratified according to MTD of ≤0.7, ≤1 and >1 cm were 50, 57 and 79%, respectively. There was a positive linear correlation between MRI and histological MTD (r = 0.42, 95% confidence interval [CI] 0.16-0.63; P = 0.002), but MRI generally underestimated the MTD: the mean MRImeasured MTD was 1.51 cm (95% CI 1.29-1.72) vs a mean pathological MTD of 2.15 cm (95% CI 1.86-2.43). Targeted biopsy identified 37% more cancer per core than non-targeted biopsy. The mean maximum core length was 8.9 mm (95% CI 7.8-10) vs 6.5 mm (95% CI 5.8-7.2) for the study vs the control group (P = 0.0002; non-paired t-test). Gleason scoring was significantly more predictive after targeted biopsies, with unchanged scores in 40/63 men (63%) vs 62/138 men (45%) in the study and control groups, respectively (P = 0.001; Fisher's test). The odds of Gleason upgrading were 2.5 times greater (P = 0.028) in the control group. The primary Gleason grade was not significantly different in the two groups [45/63 men (71%) vs 91/138 men (66%); study vs control group respectively (P = 0.51, Fisher's test)]. Overall PSMs were nonsignificantly lower in the study group (15.8 vs 18.8%; P = 0.84, Fisher's test); and the MRI location of the index tumour focus correlated with the site of PSM in 70% of men in the study group.
Introduction
In 80% of men, prostate cancer is a heterogeneous, multifocal disease with tumour foci of various sizes and Gleason grades, and oncological outcome is determined by the dominant or index tumour focus, defined as the tumour focus with the highest Gleason grade and/or the largest size [1] . Precise knowledge of the location of the index tumour focus and its size, primary Gleason grade and Gleason score should improve decision-making and assist surgical planning. In recent studies, multiparametric MRI has shown promise in predicting the site and likely aggressiveness of the index prostate tumour before biopsy, with concordance rates of 80 [2] and 90% [3] when compared with whole-gland pathology. Targeted biopsy of these foci should more precisely reflect tumour histology, and once correlated with the size and location information from the MRI data, would accurately characterize the index tumour focus.
We conducted a retrospective study of patients referred for investigation of prostate carcinoma who underwent prebiopsy 3-Tesla MRI prior to targeted biopsy of the index tumour focus, followed by robot-assisted radical prostatectomy (RARP). The general study aims were to assess whether pre-biopsy 3-Tesla prostate MRI with targeted biopsy allows accurate anatomical and oncological characterization of the index prostate tumour and if this translates into improved positive surgical margin (PSM) rates after radical prostatectomy. The primary study objective was to define the accuracy of 3-Tesla MRI in locating the index tumour focus. Secondary objectives were to assess accuracy of MRI for measurement of maximum tumour diameter (MTD) and how well the targeted biopsy reflected the true Gleason score and primary Gleason grade of the index tumour focus and whether this translated into reduced PSM status after RARP.
Patients and Methods
The study site was a specialist unit focused on the management of prostate cancer. An ethical waiver was applicable as the study was a retrospective service evaluation without any change in patient management. The unit database was used to identify all men who had undergone RARP between July 2012 and July 2014. The inclusion criteria for the study group were no known prostate cancer prior to the MRI and pre-biopsy 3-Tesla MRI <6 weeks before the biopsy. The biopsy was undertaken within our unit using the MRI data for targeting, then RARP was performed. The remaining patients were grouped together as the control group. The histology slides of the men in the control group who had undergone prostate biopsy elsewhere were reviewed by the centre's dedicated uro-pathologists, and only the reviewed biopsy data were used.
3-Tesla Multiparametric MRI Study
A 3-Tesla Avanto MRI scanner (Siemens, Erlangen, Germany) and a six-channel body matrix coil were used. Sequences acquired were axial, sagittal and coronal T2-weighted sequences, axial diffusion-weighted images and axial dynamic contrast-enhanced studies. The diffusion-weighted images were acquired at a b value of 0, 50, 100, 300, 800, 1000 and 2000 s/mm 2 . The first six diffusion-weighted imaging studies were used to calculate an apparent diffusion coefficient map. Axial dynamic contrast-enhanced studies were acquired every 7 s after an injection of 20 mg of gadopentetate dimeglumine at 3 mL/s. The studies were reported by a single uro-radiologist (U.P.) with >10 years' experience in reporting prostate MRI. The Prostate Imaging Reporting and Data System (PI-RADS) methodology was used as previously described [4] , and any suspicious foci were graded on a scale of 1-5. The index MRI focus was defined as the focus with the highest PI-RADS score. If there were two or more foci of equally high PI-RADS score, then the largest focus was designated the index tumour focus. In all cases, there was a permanent pictorial record of the MRI location of the index tumour focus in our database. The MTD of the index tumour focus was measured on the apparent diffusion coefficient maps in the axial plane.
Biopsy
The decision to progress to biopsy was undertaken by the referring urologist, and the type of biopsy carried out was dependent on the location of the index MRI focus, as well as patient preference. For example, those with deep anterior lesions were advised to undergo template-guided transperineal biopsy. Biopsies were carried out by operators with >10 years of experience with prostate biopsy, using the MRI results for visual (or cognitive) targeting, using anatomical correlation. The images were available for direct review during the biopsy on a Picture Archiving and Communication system. The live ultrasonography images were visually correlated with those from the MRI in the axial plane, until the index tumour focus was anatomically matched on the biopsy trajectories. The number of biopsy cores taken from the index tumour focus was at the discretion of the operator, but further prostate biopsies were taken according to a routine systematic pattern.
Robot-Assisted Radical Prostatectomy
The cases of all the men were discussed before surgery at a multidisciplinary team meeting attended by the operating urologists, radiation oncologists, uro-pathologists and the reporting radiologist. The biopsy findings and the MRI studies were discussed, along with the clinical data, and all the men later underwent RARP by experienced surgeons (each surgeon had performed >300 RARPs). The whole-gland specimens were analysed by the centre's uro-pathologists. Each pathology report had specific information about the Gleason grades, score, location and axial tumour length of the index tumour focus. The index tumour focus was defined as the lesion of the highest Gleason grade. If there was more than one focus of equally high Gleason grade, then the largest volume focus was designated the index site. Total tumour volume was recorded and axial histological slides through the apex, mid-gland and the base of the gland were available as a permanent pictorial record of the location of all tumour foci. A PSM was defined as tumour reaching up to the inked surface of the RARP specimen, and the size and location of each PSM was also routinely recorded.
Measurement of Study Endpoints
For the primary objective, the location of the index tumour focus on the stored magnetic resonance images was compared with its location on histology slides. For this, the position of the index focus on MRI and histology were separately mapped onto 24-sector prostate maps (Fig. 1) . The sector most occupied by the index tumour focus was designated as its location. If the index focus was large and spanned adjacent sectors, then the location was the centre of the index focus; thus, each gland could only have one sector designated as the location of the index focus on the MRI or the histological maps. MRI was counted as accurate if the MRI and histological sector locations were identical. All other instances were listed as MRI inaccurate, even if the sectors were closely adjacent on the MRI and histological maps. This binary scale was used as it is a more incisive test of the accuracy of MRI for localizing index tumour focus (Fig. 1 ).
For the secondary objectives, the MTD of the index tumour focus on MRI was compared with the histological measurement. The tumour core length, primary Gleason grade and overall Gleason score on targeted biopsy of the index tumour focus were compared with the primary Gleason grade and score of the RARP sample; and also with the results in the control group. Finally, the PSMs in the study group were compared with the PSM status in the control group.
Statistical Analysis
Patient demographics and characteristics were entered into a database for descriptive analysis. The correlation of MTD was tested by measuring the Pearson correlation coefficient and Bland-Altman plots. Continuous variables were compared using the t-test or Mann-Whitney test, as appropriate, after normality testing of the data ranges. Proportions were compared using contingency tables and the statistical tests used are given. Data were analysed using MEDCALC Statistical Software version 15.4 (MedCalc Software bvba, Ostend, Belgium) and a P value of <0.05 was taken to be significant.
Results
Of the 201 men who underwent RARP over the study period, 63 men fulfilled the inclusion criteria for the study group (Fig. 2) ; their demographics and clinical characteristics are listed in Table 1 . The other patients (n = 138) made up the control (or non-study) group. The two groups were well matched regarding risk status, with no significant differences regarding age, PSA level, prostate volume, total tumour volume and Gleason score, or pathological TNM stage (Table 2 ). More men underwent transperineal biopsy in the study group ( Table 2) .
Accuracy of MRI for the Location of the Index Tumour Focus
For this comparison, three men in the study group were omitted as we did not have whole-mount histological slides for pictorial correlation of location (Fig. 2 ). There were 157 tumour foci found on histology in the remaining 60 men from the study group (median 3 foci; range 1-7). MRI identified 74/157 of all tumour foci (47%). The MRI and histological locations of the 60 index foci are shown in Fig. 1 . MRI correctly predicted the location of the index tumour focus in 44/60 glands (73%). The accuracy for peripheral zone lesions was 35/45 (77%) and was 9/15 (60%) for anterior tumours. Accuracy was better still in those with higher PI-RADS scores and with larger tumours. A PI-RADS score of 5 correctly identified the index tumour focus in 17/ 18 cases (94%). Accuracies with PI-RADS scores 4, 3 and 2 were 18/24 (75%), 9/15 (60%) and 0/3, respectively. MRI accuracy stratified according to tumour diameter ≤0.7, ≤1 and >1 cm was 1/2 (50%), 4/7 (57%) and 41/52 (79%), respectively. An example of the often-seen close correlation between the MRI and histology locations of the index tumour focus is shown in Fig. 3 .
Accuracy of MRI for Maximum Tumour Diameter of the Index Tumour Focus
The mean maximum axial tumour diameters on MRI vs histology were 1.51 cm (95% CI 1.29-1.72) and 2.15 cm (95% CI 1.86-2.43), respectively. The distribution of the MTDs is shown in Fig. 4A , showing a moderate linear correlation between the two methods (Pearson's correlation coefficient = 0.42, 95% CI 0.16-0.63; P = 0.002). BlandAltman plots (Fig. 4B) showed that MRI underestimates the MTD by an average of 30% (average bias -0.6 units; 95% CI +1 to À2.3).
Targeted Biopsy of the Index Tumour Focus: Maximum Core Length, Gleason Score and Primary Gleason Grade
Targeted biopsy retrieved significantly greater tumour length per core biopsy and better reflected true Gleason score. The mean maximum core length was 8.9 mm (95% CI 7.8-10) vs 6.5 mm (95% CI 5.8-7.2) in the study and control groups respectively (P = 0.0002; non-paired t-test); representing 37% improved tumour length per core, with targeted biopsy.
The distribution of the biopsy Gleason score and histology are shown in 2 (n=138) Fig. 2 Patients recruited for study. MTD, maximum tumour diameter. ; study vs control group, respectively) the difference was not significant (P = 0.51, Fisher's test).
Margin Status
A total of 10 patients in the study group (15.8%) had PSMs with tumour reaching up to the inked surface of the RARP specimen. PSMs were seen in 26/138 (18.8%) cases in the control group (P = 0.84, Fisher's test); and PSMs for stage T2 disease were 3/63 (4.7%) vs 10/138 (7.2%), respectively. Sites of PSM, number with intraprostatic margins and the size of the PSM were also not significantly different between the two groups (Table 4 ). In the study group, PSMs were found in the immediate vicinity of the MRI position of the index focus in 7/10 cases (Table 5) .
Discussion
Pre-biopsy MRI and targeted biopsy provided significantly better diagnostic information in the present study. The index tumour focus was accurately localized in 73% of men, with even better performance in those with higher PI-RADS score (94% accuracy with PI-RADS 5 score) and larger index foci (76% accuracy with MTD >1 cm). Core tumour length and Gleason score were significantly longer (by 37%) and more accurate (63 vs 45%), respectively, after visually targeted or cognitive biopsy; however, MRI systematically underestimated the MTD (by a mean of 30%). Although PSMs were less frequent in those who had undergone pre-biopsy MRI and targeted biopsy, this did not reach significance in the study, but the sector location of the index focus on prostate MRI correlated with the site of PSMs in 70% of men.
Accumulating data show that multiparametric MRI can identify clinically significant cancer [5] [6] [7] [8] [9] [10] [11] [12] with an accuracy of 44-87%, sensitivity of 78% (95% CI 72-89), specificity 79% (95% CI 68-86) and a negative predictive value of 63-98% [7, 13] . The published data are heterogeneous and the definition of significant cancer is variable, often reliant on core length and Gleason grade of the biopsy sample rather than prostatectomy data. Nevertheless targeted biopsy based on MRI information detects more significant cancer (33.3 vs 23.6%) with fewer cores [14] . Although a prospective randomized study of biopsy-na€ ıve men has questioned the value of pre-biopsy MRI [15] , these are promising data. Some previous studies have focused on the role of MRI for evaluating the index tumour focus. Baco et al. [3] found a 95% accuracy regarding location and a 69.5% concordance between Gleason scores. This accuracy is better than that found in the present study, but nearly a quarter of their patients had known prostate cancer and were undergoing repeat biopsy. In a non-blinded study of the accuracy of preprostatectomy MRI, also in men with known prostate cancer [2] , 80% of index tumours were identified, especially larger and higher grade foci. These results are closer to those of the present study, with 73% accuracy for index foci and 47% for all foci in biopsy-na€ ıve men.
It has been shown that MRI performs better with higher grade disease [2, 10] and it has been proposed that men with an identified index tumour focus on pre-biopsy MRI should undergo targeted biopsy alone [11] . In a study of 125 men [16] , only 4% of significant cancers later identified on prostatectomy were missed by MRI targeted biopsy; and, in another study, missed cancers were of low grade and organconfined [13] . In the present study, the case for targeted biopsy alone with PI-RADS 5 is strong, but not for PI-RADS 4 and 3, as this would miss a number of index foci (25 and 40%, respectively). Furthermore, the range of negative predictive values reported in the literature is wide, at 63-98% [7] , and a comparative study [17] found that targeted biopsy would have missed 13% of significant cancers picked up by More values are underestimated (lie below the zero line). Table 3 Concordance of Gleason grades between core biopsy and on histology in the study and control groups.
Gleason grades on core biopsy* Gleason grades on histology
Study
In the study group all the biopsies were carried out at the centre and reported by specialist uro-pathologists. In the control group, 124/138 subjects had prostate biopsies performed elsewhere, but in all these cases, the biopsy slides underwent specialist uropathological review at the centre. The figures presented are the post-review core biopsy Gleason grades. Better biopsy performance concerning Gleason grade and score would also enhance patient management. Random prostate biopsy performs poorly, with only 53 [18] and 58% [19] score concordance. As targeted biopsy is more likely to identify clinically significant disease [7] with longer tumour core lengths, Gleason categorization should also improve. Gleason score accuracy of targeted cores was 63% in the present series, and others have reported 67 [20] and 69% [3] agreement. Although this means that about a third of Gleason scores are still inaccurate, despite targeted biopsy, most revision of Gleason score was by only one unit, in the 3 + 3 group, and usually because of an increase in the secondary Gleason grade. Practically, this means that most were revised from low (Gleason 3 + 3) to intermediate/ Gleason 3 + 4 risk category (or shift from prognostic group 1-2 in a proposed new classification) [21] .
Maximum tumour diameter is a recognized prognostic variable after prostatectomy. Despite a positive correlation, MRI underestimated the tumour length by an average of 30% in the present study, even before allowing for in vitro tumour shrinkage. This mirrors the existing literature. Previous studies have also found that MRI underestimates true tumour size [3, [22] [23] [24] . The literature suggests that diffusion-weighted images are most accurate for tumour volume estimation on MRI, with T2 sequences next and the dynamic contrastenhanced series being most error prone [25] , and that errors are more pronounced with small tumours. Measurement inaccuracy may be attributable to technical factors and could improve with better MRI resolution, but an alternative possibility is that the MRI footprint of a prostate tumour is innately smaller than the cancer itself with an MRI invisible zone on the periphery of the lesion. This is an area that requires further study.
In contemporary series [26] , PSMs after radical prostatectomy, including RARP, are seen in 6.5-32% of cases. Tumour stage and aggressiveness are most associated with PSMs. The average stage-specific PSM rate for T1 disease is 9%, compared with 37% for stage T3. Indirect characteristics thought to be associated with PSMs are surgical experience, prostate gland volume and body mass index [26] . Better preoperative planning and careful surgical technique have been emphasized as a means of reducing PSMs [27] . In the past, imaging was thought not sufficiently reliable for preoperative mapping [27] , but, as the present study shows, modern multiparametric MRI has a high sensitivity for identifying the location of aggressive tumour foci. This information should help surgical planning but a beneficial impact of MRI on PSM rates remains to be proven. The sector location of the MRI index tumour focus correlated with the site of PSMs in 70% of men in our series and an association between index focus position and margin positivity has also been reported by others [28] . Yet, we were not able to prove that MRI characterization and targeted biopsy translated into significantly better PSM rates, although there was a trend towards this (overall PSM rate 15.8 vs 18.8%, T2 PSM rates 4.7 vs 7.2%). Rud et al. [29] were also unable to show that PSMs were significantly better in those who had undergone pre-biopsy MRI (23 vs 19%) , except with T1 tumours (27 vs 16%). It is possible that our sample size, and also those of other studies [29] , was too small to measure a true difference and larger studies are therefore necessary. With a large sample size, other aspects that may affect PSMs could also be studied, such as how surgical planes should be modified if the capsular breach is suspected to be microscopic rather than overt on MRI, or if the index focus is located in the apex vs the base of the prostate gland. The strengths of the present study are that the MRI studies and the biopsy and whole-gland pathology were interpreted by a specialist uro-radiologist and uro-pathologists, respectively, which should have reduced observer variability. Furthermore, all measurement indices for the study objectives were already available in the database and comparisons were made with the robust standard of prostatectomy data. There were no data re-reading for study purposes. Thus, this is a service evaluation of routine practice, but there are also some study limitations. Firstly, the study group was a retrospectively selected cohort of modest numbers. The confidence intervals for some of our measurements were wide and there is a risk of type 2 statistical error. The control group all underwent their biopsies elsewhere, and although central review of the biopsy slides should have reduced observer variability regarding Gleason grading, this group was heterogeneous regarding number of cores and biopsy techniques. We used visual cognitive (or visual) targeting for index tumour focus biopsy, rather than MRI-ultrasonography fusion techniques advocated elsewhere [30] . The accuracy of MRI-ultrasonography fusion techniques for detection of significant prostate cancer was estimated at~59%, compared with 54% accuracy for cognitive targeting [11] , but the two studies that have formally compared the accuracy of these two targeting methods have reported mixed results [31, 32] . Others have observed that cognitive targeting requires greater expertise [30] . Targeted biopsies in the present study were carried out by experienced operators but if MRIultrasonography fusion biopsy is indeed superior to cognitive targeting, then the results of targeted biopsy for characterization of the index tumour focus would be even better than reported in the present study. Lastly, all patients in the study underwent a 3-Tesla MRI study and the findings may not be generalizable to lower-strength machines.
Although not proven, 3-Tesla MRI is believed to perform better than 1.5-Tesla and is the choice of experts in this field [33] .
In conclusion, pre-biopsy 3-Tesla multiparametric MRI can accurately locate the index prostate tumour focus (overall accuracy 73%), especially in those with PI-RADS 4 and 5 lesions (accuracies 75 and 94%, respectively). Targeted biopsy of these index foci performs significantly better with longer tumour core lengths and more accurate Gleason scoring; however, MRI underestimates the size of the index tumour focus. MRI and targeted biopsy data can help surgical planning, but more data are required to confirm whether this translates into significantly improved PSM rates.
